IMV Inc. (IMV) Reports Q2 Loss of $0.13/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
IMV Inc. Announces Second Quarter 2020 Financial Results
August 12, 2020 7:05 AM EDTRapidly progressing DPX-COVID-19, including Health Canada agreement on Phase 1 clinical study design protocol, with preliminary results expected in fall 2020 Confirmed $4.75M of non-dilutive fund supporting Phase 1 clinical development of DPX-COVID-19 Updated data from Phase 2 DeCidE1 study with a 26% clinical response rate highlighting the potential of DPX-Survivac to improve the standard of care in advanced ovarian cancer Pro-forma cash and cash equivalents of $61.8M on June 30th, 2020 Management to host a conference... More
